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Abstract
Background: Ertapenem, a new carbapenem with a favorable pharmacokinetic profile, has been
approved for the treatment of complicated intra-abdominal Infections (cIAIs), acute pelvic
infections (APIs) and complicated skin and skin-structure infections (cSSSIs). The aim of this study
is to compare the efficacy and safety of ertapenem with piperacillin/tazobactam, which has been
reported to possess good efficacy for the treatment of these complicated infections.
Methods: We performed a meta-analysis of randomized controlled trials identified in PubMed,
Cochrane library and Embase that compared the efficacy and safety of ertapenem with piperacillin/
tazobactam for the treatment of complicated infections including cIAIs, APIs, cSSSIs. The primary
efficacy outcome was clinical treatment success assessed at the test-of-cure visit. The primary
safety outcome was drug related clinical and laboratory adverse events occurred during the
treatment and the post-treatment period.
Result: Six RCTs, involving 3161 patients, were included in our meta-analysis. Ertapenem was
associated similar clinical treatment success with piperacillin/tazobactam for complicated infections
treatment (clinically evaluable population, 1937 patients, odds ratios: 1.15, 95% confidence
intervals: 0.89-1.49; modified intention to treat population, 2855 patients, odds ratios: 1.03, 95%
confidence intervals: 0.87-1.22). All of secondary efficacy outcomes analysis obtained similar
findings with clinical treatment success. No difference was found about the incidence of drug
related adverse events between ertapenem and piperacillin/tazobactam groups.
Conclusion: This meta-analysis provides evidence that ertapenem 1 g once a day can be used as
effectively and safely as recommended dose of piperacillin/tazobactam, for the treatment of
complicated infections, particularly of mild to moderate severity. It is an appealing option for the
treatment of these complicated infections.
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Background
The treatment of complicated infections such as compli-
cated intra-abdominal infections (cIAIs), acute pelvic
infections (APIs) and complicated skin and skin-structure
infections (cSSSIs) is a challenge for clinicians. They are
most often polymicrobial or mixed infections which
caused by pathogens involving a mixture of gram-positive
and gram-negative aerobic and anaerobic organisms
including staphylococcus, streptococci, enterococci,
Enterobacteriaceae, anaerobic coccobacilli, anaerobic
bacilli [1-4].
The outcome of complicated infections depends on the
timely diagnosis and treatment which involves appropri-
ate antimicrobial therapy directing to the residual infect-
ing microorganisms. Absent or inadequate antibiotic
therapy results in both increased failure rates and mortal-
ity. Empiric antimicrobial treatment of the complicated
infection requires parenteral coverage of a broad spectrum
of potential pathogens, often including β-lactam/β-lacta-
mase inhibitor combination, carbapenems, cepha-
losporins with anaerobic coverage, or combination
therapy consisting of a cephalosporin, fluoroquinolone,
or aminoglycoside plus an anti-anaerobic agent [5-7].
Ertapenem (Merck & Co., Inc., USA), a long-acting and
once-daily parenteral carbapenem, was approved for the
treatment of complicated infections such as cIAIs, APIs,
cSSSIs. It is rapidly bactericidal against most of the pre-
dominant intra-abdominal, skin/skin-structure and pelvic
pathogens, including many that produce extended-spec-
trum or AmpC β-lactamase producing Enterobacteriaceae
which are resistant to cephalosporins and β-lactam/β-
lactamase inhibitor combination [8-10]. It is an appealing
option for the treatment of these complicated infections
not only because of its spectrum of antimicrobial activity,
but also its convenient dosing schedule, and sounds a use-
ful alternative for combination and/or multidosed antibi-
otic regimens for the empiric treatment.
Although ertapenem has limited activity in vitro against
enterococci and Pseudomonas aeruginosa which may be
encountered in cIAIs, APIs and cSSSIs, several randomized
controlled trials (RCTs) suggested that ertapenem is at
least as effective as piperacillin/tazobactam, a β-lactam/β-
lactamase inhibitor combination agent that is routinely
used in the treatment of these complicated infections [11-
16]. Aiming to compare more conclusively the efficacy
and safety of ertapenem with piperacillin/tazobactam in
these complicated infections, we undertook a system
review with meta-analysis of relevant RCTs.
Methods
Data sources
The study was done with a prespecified search strategy and
study eligibility criteria. We did an extensive electronic
search of PubMed (up to March 2009), the Cochrane Cen-
tral Register of Controlled Trials (Cochrane Library Issue
1, 2009), and Embase (1980 to March 2009) to identify
relevant RCTs for our meta-analysis, without language
restrictions. We restricted the search to randomized con-
trolled trials. Search term combinations were "ertap-
enem" "piperacillin/tazobactam" "polymicrobial
infections" and similar, "mixed infections" and similar,
"complicated intra-abdominal infections", "complicated
skin and skin-structure infections", "acute pelvic infec-
tions". All reference lists from the relevant articles and
reviews were hand searched for additional eligible studies.
Experts in the field were also consulted. The articles that
were not available to us were requested from the authors.
Study selection
Two reviewers (MMA and ZZ) independently searched the
literature and examined relevant RCTs for further assess-
ment. Any study was included in our meta-analysis if it
was a RCT; if it involved patients of all ages with cIAIs,
APIs, cSSSIs or other complicated infections; if it com-
pared the efficacy and safety of ertapenem with piperacil-
lin/tazobactam; if it reported specific data regarding
clinical treatment success, microbiological treatment suc-
cess, mortality, adverse events. Trials with blinded and
unblinded design were both included. Abstracts in scien-
tific conferences were not included in the meta-analysis.
Experimental trials and trials focusing on pharmacoki-
netic or pharmacodynamic variables were excluded.
Qualitative assessment
Evaluation of the methodological quality of the RCTs
included in the meta-analysis was performed independ-
ently by the two reviewers (MMA and ZZ) using the Jadad
scoring system as follows: One point is awarded for the
presence of randomization, blinding and data about
study withdrawals respectively. Also, if the randomization
or blinding procedures are appropriate, one point is
awarded for each procedure; no points are awarded if no
data are provided regarding the methodology of the
above-mentioned procedures; finally, if any of these pro-
cedures is not deemed appropriate one point is deducted
for each one [17]. The maximum score that can be attrib-
uted to an RCT is 5. An RCT with a score higher than 2 is
considered as an RCT of adequately good quality [18,19].
Data extraction
Two reviewers (MMA and ZZ) independently extracted
data from included trials. Data were extracted from each
study with a predesigned review form. In case of any disa-
greement between the two reviewers, a third reviewer
extracted the data and results were attained by consensus.
We contacted the authors of trials for missing data when
necessary.BMC Infectious Diseases 2009, 9:193 http://www.biomedcentral.com/1471-2334/9/193
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The following data were extracted from each study: year of
publication, clinical setting, patient population, and
number of patients (intention to treat [ITT], modified
intention to treat [MITT], clinically and microbiologically
evaluable populations), antimicrobial agents and doses
used, concomitant antibacterial agents, clinical and
microbiological outcomes, mortality and drug related
adverse events. The MITT population was composed of
randomized patients who received at least one dose of
study drug and met the minimal disease definition. The
clinically evaluable population comprised patients that
fulfilled all inclusion and exclusion criteria in the individ-
ual RCTs, had complete follow-up, and for whom data on
treatment outcomes were available but not indeterminate.
The microbiologically evaluable population was a subset
of the clinically evaluable population that had also micro-
biologically documented infections.
Definitions of infections
Infections were defined according to the definitions used
by the individual RCTs. Definitions of infections did not
differ substantially between the RCTs included in the
meta-analysis.
cIAIs were defined as intra-abdominal infections extend-
ing beyond site of origin, causing peritonitis or abscess
formation, and thus requiring surgical intervention. APIs
were defined clinically by the presence of fever (>38°C) or
a white blood cell count >10 500/μl plus pelvic or abdom-
inal or uterine pain or cramping or tenderness, or an
imaging study suggesting pelvic abscess or infection; and
a compatible prior gynecological history. cSSSIs were
defined as skin and skin-structure infections with suffi-
cient severity and signs of systemic illness, which is
deeper, more indolent, and more severe than routine soft-
tissue infections, such as perineal cellulitis or abscesses,
extensive cellulitis, posttraumatic or postsurgical skin or
soft-tissue infection, and lower-extremity infections in
patients with diabetes mellitus.
Analyzed outcomes
The primary efficacy outcome of this meta-analysis was
clinical treatment success(defined as complete resolution
or substantial improvement of symptoms and signs of
cIAIs, cSSSIs, and APIs, or no further antimicrobial ther-
apy and surgical intervention for infection was necessary)
assessed at the test-of-cure (TOC) visit employed in each
individual study. The secondary efficacy outcome was
microbiological treatment success (defined as the eradica-
tion of baseline pathogens, or as presumed eradication
based on the clinical outcomes when post-treatment cul-
tures were not performed) and mortality. The analysis of
efficacy outcomes were based on MITT and clinically eval-
uable populations in each included RCT.
The primary safety outcome of the meta-analysis was clin-
ical and laboratory drug related adverse events (defined as
any adverse events which deemed to be drug related, and
observed during the treatment and the post-treatment
period) in each included RCT.
Data analysis and statistical methods
Statistical analysis were done with Review Manager ver-
sion 5.0.17 (Cochrane Collaboration, Oxford, UK). We
assessed heterogeneity of trial results by calculating a chi-
square test of heterogeneity and the I2 measure of incon-
sistency. The publication bias was assessed by examining
the funnel plot. We used a fixed-effect model (FEM) by
using the Mantel-Haenszel method for pooling odds
ratios (ORs) and 95% confidence intervals (CIs) for all
primary and secondary outcomes (including MITT, clini-
cally evaluable, and microbiologically evaluable popula-
tions) throughout the meta-analysis unless statistically
significant heterogeneity was found (p < 0.10 or I2 >
50%), in which case we chose a random-effects model
(REM) and used the DerSimonian and Laird method. Het-
erogeneity was investigated through subgroup analysis as
defined above.
Results
Study selection process
The flow diagram (Figure 1) showed the detailed screen-
ing and selection process for the trials included in this
meta-analysis. The search was performed in PubMed, the
Cochrane Central Register of Controlled Trials and
Embase. We obtained 19 full papers from 44 studies for
detail evaluation. Finally, we identified 6 RCTs, which ful-
filled the criteria for inclusion in the meta-analysis.
Study characteristics
The main characteristics of the 6 included RCTs (type of
study design, characteristics of the included population,
antimicrobial agents and doses used, concomitant anti-
bacterial agents, number of enrolled patients and ITT
patients, Jadad score) presents in Table 1. All of the
included RCTs were performed exclusively in adult
patients (three RCTs involved patients with cIAIs, 2 RCTs
involved patients with cSSSIs and 1 RCTs involved exclu-
sively adult female patients with APIs). High Jadad score
(four RCTs had a score of 5, one had 4 and one had 3)
indicated high quality of the RCTs included in the meta-
analysis. We examined the funnel plot (SE of log OR plot-
ted against ORs) to estimate publication bias, showing a
symmetric inverse funnel distribution.
Regarding the characteristics of the population of the
included RCTs involving patients with cIAIs, it was specif-
ically reported that patients with severe infections
(APACHE II score > 30[11,12,14]) were excluded. Most of
the trials only included patients infected with pathogensBMC Infectious Diseases 2009, 9:193 http://www.biomedcentral.com/1471-2334/9/193
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susceptible to study antimicrobial treatments or with at
least one pathogen being susceptible to study treatments
in the case of polymicrobial infections, and excluded the
patients with infections caused by pathogens known to be
resistant to study treatments. In 5 of the overall 6 included
RCTs, other than vancomycin or teicoplanin to treat infec-
tions caused by resistant gram-positive pathogens, con-
comitant use of other antimicrobial agents was not
allowed. In the other one RCT [15], any concomitant use
of other antimicrobial agents was not permitted.
All the patients in the ertapenem treatment arms received
1 g of ertapenem intravenously once daily. Except partial
patients in trial performed by Dela Peta et al [11] received
4.5 g of piperacillin/tazobactam every 8 hours, all the
other patients in piperacillin/tazobactam groups included
in our meta-analysis received 3.375 g every 6 hours. The
duration of administration of study treatments varied
between studies, but no differences were found between
the compared arms, in each individual RCT. We analysis
all of the outcomes assessed at TOC visit which varied
between the RCTs, with a minimum value of 10 days, to a
maximum value of 4 weeks, after the completion of study
treatments.
Clinical treatment success and mortality
All of the 6 relevant RCTs provided the primary outcome
(clinical treatment success) of the patients with compli-
cated infections. The total clinical treatment success of
ertapenem group was numerically higher than piperacil-
lin/tazobactam group in clinically evaluable population
at TOC visit, while no significant difference was found
(1937 patients, FEM, OR: 1.15, 95% CI: 0.89-1.49, Figure
2A). The similar results were confirmed in the conserva-
Flow diagram of the randomized controlled trials (RCTs) reviewed Figure 1
Flow diagram of the randomized controlled trials (RCTs) reviewed.
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tive MITT analysis in which patients with inadequate
information or indeterminate outcomes were considered
to be cases of treat failure (2855 patients, FEM, OR: 1.03,
95% CI: 0.87-1.22, Figure 2B).
Regarding the cIAIs and APIs or cSSSIs subgroup, there
was also no significant difference in treatment success
between the clinically evaluable patients treated with
ertapenem, and those treated with piperacillin/tazo-
bactam at TOC visit (cIAIs and APIs subgroup, 4 RCTs,
1176 patients, FEM, OR: 1.18, 95% CI: 0.83-1.67; cSSSIs
subgroup, 2 RCTs, 761 patients, FEM, OR: 1.11, 95% CI:
0.75-1.64, Figure 2A). The conservative MITT analysis
confirmed the above results (cIAIs and APIs subgroup, 4
RCTs, 1754 patients, FEM, OR: 1.01, 95% CI: 0.81-1.28;
cSSSIs subgroup, 2 RCTs, 1101 patients, FEM, OR: 1.05,
95% CI: 0.81-1.36, Figure 2B).
Four of the 6 relevant RCTs provided mortality outcomes
of the included patients. There was also no significant dif-
ference in mortality between the patients treated with
ertapenem, and those treated with piperacillin/tazo-
Table 1: Main characteristics of the trials included in the meta-analysis
Study Type of 
study
Included 
population
Drug tested concomitant 
antibacterial 
agents
Enrolled 
patients
Intention 
to treat
Jadad score
Ertapenem Piperacillin/
tazobactm
Dela Pena et 
al.
Multicentre
open-label
RCT
Hospitalized 
adults, ≥18 
years-old, with 
cIAIs that 
extended 
beyond the wall 
of a hollow 
organ
Ertapenem 1 g 
once daily, 
i.v.(possible 
change to i.m. 
after 2 days of 
therapy)
Piperacillin/
tazobactm 3.375 
g i.v. q6h or 4.5 
g i.v. q8h
Vancomycin 
or teicoplanin, 
for resistant 
Gram-positive 
pathogens
399 180vs190 3
Namias et al. Multicentre
double-blind
RCT
Hospitalized 
adults,18-90 
years-old, with 
presumptive or 
confirmed cIAIs
Ertapenem 1 g 
once daily, i.v., 
followed by a 
placebo every 6 
h for three 
additional doses 
daily
Piperacillin/
tazobactm
3.375 g i.v. q6h
Vancomycin if 
MRSA or 
enterococci 
isolated
500 247vs247 5
Roy et al. Multicentre
double-blind
RCT
Females ≥16 
years-old, With 
APIs, required 
≥3 days of 
parenteral 
antimicrobial 
therapy
Ertapenem 1 g 
once daily, i.v., 
followed by a 
placebo every 6 
h for three 
additional doses 
daily
Piperacillin/
tazobactam 
3.375 g i.v. q6h 
(adjusted in case 
of low 
creatinine 
clearance).
Vancomycin 
for resistant 
Gram-positive
organisms, 
antifungals
450 216vs196 5
Solomkin et 
al.
Multicentre
double-blind
RCT
Hospitalized 
adults ≥18 
years-old, with 
confirmed cIAIs
Ertapenem 1 g 
once daily, i.v., 
followed by a 
placebo every 6 
h for three 
additional doses 
daily
Piperacillin/
tazobactam 
3.375 g i.v. q6h 
(adjusted for 
renal failure)
Vancomycin 
against 
enterococci 
or MRSA
633 323vs310 5
Graham et al. Multicentre
double-blind
RCT
adults ≥18 
years-old, with 
CSSSIs, required 
parenteral 
antimicrobial 
therapy
Ertapenem 1 g 
once daily, i.v., 
followed by a 
placebo every 6 
h for three 
additional doses 
daily
Piperacillin/
tazobactam 
3.375 g i.v. q6h
Not 
permitted
540 274vs266 4
Lipsky et al. Multicentre
double-blind
RCT
diabetes mellitus 
adult patients, 
with a foot 
infection that did 
not extend 
above the knee
Ertapenem 1 g 
once daily, i.v., 
followed by a 
placebo every 6 
h for three 
additional doses 
daily
Piperacillin/
tazobactam 
3.375 g i.v. q6h
Vancomycin 
against 
enterococci 
or MRSA
639 295vs291 5BMC Infectious Diseases 2009, 9:193 http://www.biomedcentral.com/1471-2334/9/193
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Meta-analysis of clinical treatment success and mortality comparing ertapenem with piperacillin/tazobactam for complicated  infections treatment at test-of-cure visit Figure 2
Meta-analysis of clinical treatment success and mortality comparing ertapenem with piperacillin/tazobactam 
for complicated infections treatment at test-of-cure visit. A, clinical treatment success analysis based on clinically eval-
uable population; B, clinical treatment success analysis based on modified intention to treat population; C, mortality analysis. 
Vertical line indicates no difference between ertapenem and piperacillin/tazobactam. The size of each square denotes the pro-
portion of information given by each trial.BMC Infectious Diseases 2009, 9:193 http://www.biomedcentral.com/1471-2334/9/193
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bactam at TOC visit (2032 patients, FEM, OR: 1.02, 95%
CI: 0.63-1.65, Figure 2C).
The sensitivity analysis limited to double-blind RCTs,
obtained similar finding regarding clinical treatment suc-
cess in clinically evaluable population(5 RCTs, 1704
patients, FEM, OR: 1.21, 95% CI: 0.93-1.59) and MITT
population (5 RCTs, 2494 patients, FEM, OR: 1.05, 95%
CI: 0.88-1.26), and regarding mortality outcome (3 RCTs,
1662 patients, FEM, OR: 1.18, 95% CI: 0.68-2.03).
Microbiological treatment success
All the 6 relevant RCTs provided the microbiological treat-
ment success. The total microbiological treatment success
of ertapenem group was numerically higher than pipera-
cillin/tazobactam group in microbiologically evaluable
population at TOC visit, while there was no significant
difference (1699 patients, FEM, OR: 1.11, 95% CI: 0.84-
1.47, Figure 3).
In the subgroup analysis including with cIAIs and APIs, no
difference was found regarding microbiological treatment
success between ertapenem and piperacillin/tazobactam
treatment arm (4 RCTs, 1107 patients, FEM, OR: 1.11,
95% CI: 0.76-1.61, Figure 3). In the additional subgroup
analysis including patients with cSSSIs, there was also no
difference between compared treatment arms (2 RCTs,
592 patients, FEM, OR: 1.11, 95% CI: 0.72-1.71, Figure
3).
In the sensitivity analysis limited to double-blind RCTs,
we got unchanged findings with the overall analysis
regarding microbiological treatment success (5 RCTs,
1475 patients, FEM, OR: 1.17, 95% CI: 0.88-1.57).
Drug related adverse events
Four of the 6 relevant RCTs provided the drug related clin-
ical adverse events and 5 provided laboratory adverse
events. The total drug related adverse events of ertapenem
groups were slightly lower than piperacillin/tazobactam
groups in safety evaluable population.
The most common drug related clinical adverse events in
each treatment group (ertapenem vs. piperacillin/tazo-
bactam recipients) were gastrointestinal, most commonly
diarrhea, vomiting and nausea. These were generally of
mild to moderate severity. No difference was found
regarding drug related clinical adverse events between
ertapenem and piperacillin/tazobactam treatment arms
(1885 patients, FEM, OR: 0.95, 95% CI: 0.76-1.20, Figure
4A).
The most common drug related laboratory adverse events
were increased liver transaminases (alanine aminotrans-
ferase and aspartate aminotransferase), increased serum
alkaline phosphatase, and thrombocytosis. These eleva-
tions were generally mild to moderate and were transient,
where follow-up information was available in the
included RCTs. No other specific drug related adverse
Meta-analysis of microbiological treatment success comparing ertapenem with piperacillin/tazobactam for complicated infec- tions treatment at test-of-cure visit Figure 3
Meta-analysis of microbiological treatment success comparing ertapenem with piperacillin/tazobactam for 
complicated infections treatment at test-of-cure visit. The analysis based on microbiologically evaluable population. 
Vertical line indicates no difference between ertapenem and piperacillin/tazobactam. The size of each square denotes the pro-
portion of information given by each trial.BMC Infectious Diseases 2009, 9:193 http://www.biomedcentral.com/1471-2334/9/193
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events occurred in >3% of patients in either treatment
group. The analysis regarding drug related laboratory
adverse events got similar results with the drug related
clinical adverse events (2290 patients, REM, OR: 0.88,
95% CI: 0.57-1.37, Figure 4B).
The sensitivity analysis limited to double-blind RCTs,
obtained similar findings with the overall analysis regard-
ing either clinical adverse events (3 RCTs, 1515 patients,
FEM, OR: 0.93, 95% CI: 0.72-1.19), or laboratory adverse
events (4 RCTs, 1920 patients, REM, OR: 0.83, 95% CI:
0.50-1.37).
Discussion
This systematic review with a meta-analysis compared the
efficacy and safety of ertapenem with piperacillin/tazo-
bactam in patients with complicated infections including
cIAIs, APIs and cSSSIs. The main result of this meta-anal-
ysis with regard to the primary efficacy outcome (clinical
treatment success) suggested that no difference existed
between the treatment arms (Figure 2). The secondary
outcome analysis produced finding consistent with the
primary outcome (Figure 2, 3). In the ertapenem treat-
ment arms, the drug related clinical adverse events mainly
were gastrointestinal and the drug related laboratory
Meta-analysis of drug related adverse events comparing ertapenem with piperacillin/tazobactam for complicated infections  treatment during the treatment and the post-treatment period Figure 4
Meta-analysis of drug related adverse events comparing ertapenem with piperacillin/tazobactam for compli-
cated infections treatment during the treatment and the post-treatment period. The analysis based on safety eval-
uable population. A, analysis of clinical drug related adverse events; B, analysis of laboratory drug related adverse events; 
Vertical line indicates no difference between ertapenem and piperacillin/tazobactam. The size of each square denotes the pro-
portion of information given by each trial.BMC Infectious Diseases 2009, 9:193 http://www.biomedcentral.com/1471-2334/9/193
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adverse events consisted primarily of elevations in liver
enzymes (transaminases and alkaline phosphatase) and
thrombocytosis. The safety analysis regarding to the drug
related clinical and laboratory adverse events both proved
no difference between the compared treatment arms (Fig-
ure 4). Likewise, post hoc analysis of trials comparing
ertapenem treatment with piperacillin/tazobactam, in
patients with cIAIs, APIs and cSSSIs, also have not
revealed any significant differences, regarding the efficacy
and safety outcomes examined [20].
An earlier meta-analysis performed by Falagas et al
[21]had provided evidence that ertapenem was compara-
ble to other recommended antimicrobial regimens (piper-
acillin/tazobactam, ceftriaxone plus metronidazole and
ticarcillin/clavulanic acid) for the treatment of cIAIs. The
focus of our meta-analysis was to compare the efficacy
and safety of ertapenem with piperacillin/tazobactam, a
well-established therapeutic agent, in patients with com-
plicated infections. APIs, cSSSIs and cIAIs are most often
polymicrobial infections. They have similarities both in
aetiological organisms involving a mixture of gram-posi-
tive, gram-negative anerobic and anaerobic organisms
such as staphylococcus, streptococci, enterococci, Entero-
bacteriaceae, anaerobic coccobacilli, anaerobic bacilli,
and in empiric antimicrobial treatment that requires
parenteral coverage of a broad spectrum of potential path-
ogens including an extended-spectrum cephalosporin
plus an agent active against anaerobes including an
extended-spectrum cephalosporin plus an agent active
against anaerobes, such as metronidazole or clindamycin,
or a β-lactam/β-lactamase inhibitor combination. Pipera-
cillin/tazobactam, a β-lactam/β-lactamase inhibitor com-
bination agent, has been well studied and is approved in
the treatment of complicated infection including cIAIs,
APIs, and cSSSIs [22]. So in the present meta-analysis, we
included RCTs performed on APIs and cSSSIs, in addition
to those performed on cIAIs.
It should be pointed out that ertapenem, although highly
active in vitro against methicillin-susceptible staphyloco-
cci and most clinically important Enterobacteriaceae,
streptococci and anaerobes which are the most common
causal pathogens in cIAIs, APIs and cSSSIs, is not against
non-fermentative gram-negative bacilli, such as Pseu-
domonas aeruginosa, which are important nosocomial
pathogens, particularly in intensive care units, or entero-
cocci, which in the setting of a polymicrobial infection are
of questionable pathogenicity[23,24]. Notably, in our
meta-analysis ertapenem had a comparable efficacy (Fig-
ure 2, 3) to piperacillin/tazobactam, an agent possessing
antienterococcal and good antipseudomonal activity.
Clinical and microbiologic success rates for patients
infected with Pseudomonas aeruginosa or enterococci were
generally similar in each relevant RCT, and the high favo-
rable response rates implied routine enterococcal or pseu-
domonal coverage was not essential, which was consistent
with previous study [25-27] and the current recommenda-
tions from the Surgical Infection Society [28] and the
Infectious Disease Society of America [29]. However, this
finding should be interpreted with caution, given that it is
based on a rather small total number of patients in our
meta-analysis.
Although the present evidence suggests ertapenem had
similar efficacy and safety profile with piperacillin/tazo-
bactam in the treatment of complicated infections such as
cIAIs, APIs and cSSSIs, several unique characteristics make
it as an alternative to piperacillin/tazobactam. Firstly,
ertapenem may mitigate the emergence of resistant
strains. Previous studies indicated that there were fewer
instances of emergence of resistant Enterobacteriaceae
and extended-spectrum β-lactamase producing Entero-
bacteriaceae in the colonizing bowel flora of ertapenem-
treated patients with cIAIs than receiving piperacillin/
tazobactam or ceftriaxone plus metronidazole, and there
were no differences between groups in the prevalence of
imipenem-resistant Pseudomonas in the colonizing bowel
flora after completion of therapy [30,31]. This may be
attributed to the limited development of microbial resist-
ance to carbapenems and the targeted spectrum of ertap-
enem [32]. Secondly, once-daily dosing of ertapenem may
offer benefits compared with agents that require multiple
dosing or combination therapy, including patient conven-
ience and comfort, and a lower risk of medication errors
[32]. Thirdly, compared with piperacillin/tazobactam
given four times daily i.v., ertapenem given once daily i.v.
was associated with lower drug and supply costs and less
time and labor devoted to the preparation and adminis-
tration of i.v. therapy[33].
In contrast to the earlier meta-analysis [21], we examined
6 high quality RCTs (Four RCTs had a Jadad score of 5,
one had 4 and one had 3), focused on direct comparison
of treatments with ertapenem and piperacillin/tazo-
bactam as monotherapy, precluding the interference of
other drugs, and included RCTs performed on APIs and
cSSSIs in addition to cIAIs. The efficacy and safety out-
come of our meta-analysis were defined similarly in the
individual trial. Furthermore, the same administration
route and doses of ertapenem (1 g once daily, i.v.) was
used to compare with recommended dose of piperacillin/
tazobactam in patients of the included RCTs. So the simi-
lar treatment schedule and evaluation criteria of the
included trials provided greater statistical confidence for
our meta-analysis.
The meta-analysis is not without limitations. First, the
clinical treatment success analysis based on the data
defined as cure or improvement of signs and symptomsBMC Infectious Diseases 2009, 9:193 http://www.biomedcentral.com/1471-2334/9/193
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may not be as accurate as complete cure. Four of the 6
overall included studies provided mixed data regarding
the outcome of clinical treatment success. This may
hinder a meaningful separate meta-analysis of complete
cure. Second, in 3 RCTs performed on cIAIs, patients with
severe infections (APACHE II score > 30 or of a life-threat-
ening degree) were excluded, so the finding of this meta-
analysis should be interpreted with caution on severe
infections. Third, most included RCTs excluded patients
with infections caused by pathogens known to be resistant
to study treatment, which may interfere with the finding.
Finally, all of the 6 included trials, including the one non-
blinded study, were supported by the branding pharma-
ceutical company of ertapenem, a factor that might
generate bias in the assessment of outcomes. Neverthe-
less, the sensitivity analysis limited to double-blind RCTs
was performed in our meta-analysis, resulting in findings
consistent with those of the primary analysis.
Conclusion
Despite the limitations, the efficacy of ertapenem 1 g once
daily was statistically equivalent to recommended dose of
piperacillin/tazobactam, and was generally well tolerated.
The present evidence suggests that the clinical use of ertap-
enem is associated with decreased emergence of antimi-
crobial resistance and lower costs. The once-daily dosing
of ertapenem may be a useful alternative for combination
and/or multidosed antibiotic regimens for the empiric
treatment. However, there is rather limited evidence for
the efficacy of ertapenem compared to piperacillin/tazo-
bactam, in patients with severe complicated infections
caused by one or more pathogens.
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